Competition To Cooperation: Indian And Chinese Firms Agree On Draft MOU For Partnerships, Investments And GMP Training
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Intense price competition in key developed markets and common concerns for quality products and GMP issues is set to bring India and China together to boost collaborative efforts
You may also be interested in...
Pushed By Rising Costs And Slow Approvals, India’s Dishman Set To Retreat From China
Dishman’s move follows similar moves from Indian peers like Dr. Reddy’s and Ranbaxy, which have also soured on the Chinese market.
In API Battle, China Chips Away At India’s Share; India Calls For Policy Safeguards
China is becoming a serious threat to India’s indigenous API manufacturers, as India seeks policy safeguards such as anti-dumping duties and stricter inspections on Chinese imports.
Heparin Crisis Leads To New U.S. FDA Policy On Consulting Outside Experts
U.S. FDA's new policy for retaining outside experts in emergency situations calls for the agency to consider the risks posed by the collaboration as well as requirements for conflict-of-interest screening and disclosure